Sign up
Pharma Capital
EPIC: C4XD
Market: AIM
52-week High/Low: 114.96p / 33.25p
Sector: Health Care, Equipment & Services
Market Cap: 27.74M

C4X Discovery aims to become the world's most productive drug discovery engine by exploiting cutting edge technologies to design and create best-in-class small-molecule candidates targeting a range of high value therapeutic areas. The company's goal is to drive returns through early-stage revenue-generating deals with the pharmaceutical industry.

C4X Discovery Holdings plc

www.c4xdiscovery.com

Interactive graph

col 3
col 4
col 5
col 6

Big picture - Why invest in C4X Discovery Holdings plc

C4X Discovery Holdings plc Snapshot

C4X Discovery has a state-of-the-art suite of proprietary technologies across the drug discovery process. The company's innovative DNA-based target identification platform (Taxonomy3®) utilises human genetic datasets to identify novel patient-specific targets leading to greater discovery productivity and increased probability of clinical success. This is complemented by C4XD's novel drug design platform which comprises two innovative chemistry technologies, Conformetrix and Molplex, that combine 4D molecular shape analyses (based on experimental data) with best-in-class computational chemistry. This provides new and unprecedented insight into the behaviour of drug molecules, enabling the production of potent selective compounds faster and more cost effectively than the industry standard.

C4X Discovery is advancing its in-house pipeline that is primarily focused on the high value therapeutic areas of inflammation, neurology and cancer (including immuno-oncology) with a number of new drug candidates identified and further progress made towards the pre-clinical licensing discussions. In selecting new targets and executing new drug discovery programmes, C4X Discovery focuses on high-value disease areas that are the subject of significant licensing activity and will continue to also maximise value from opportunistic areas such as addiction and diabetes. The Company recently signed a licensing agreement with Indivior for a pre-clinical addiction programme worth up to $294 million.

The Company was founded as a spin-out from the University of Manchester. It has a highly experienced management team and Board who have delivered significant value creation within the healthcare sector historically and have enabled C4XD to reach multiple value inflexion points since IPO.

c4xd about moleule with vr

 

DRUG DISCOVERY PIPELINE
Highly Valuable Markets

C4X Discovery is using its unique proprietary technologies to build a pipeline of high quality small molecule drug candidates addressing valuable markets with high unmet medical need.

c4x pipeline 2019

C4X Discovery continues to advance its in-house pipeline that is primarily focussed on the high value therapeutic areas of immunology/inflammation, neurology/neurodegeneration and cancer (including immuno-oncology) as these areas are subject to the most significant R&D licensing activity in the pharmaceutical sector (BIO Industry Analysis, “Emerging, Therapeutic Company Investment and Deal Trends”, May 2018).

1. 4 additional early discovery programmes currently paused due to insufficient chemical opportunity

2. Disease targets with high commercial opportunity and partnering potential against which C4X’s proprietary drug discovery technologies can provide a competitive advantage in development.

TECHNOLOGY
Underpinning the world's most productive drug discovery engine

C4X Discovery aims to become the world’s most productive drug discovery and development company by exploiting cutting-edge technologies to design and create best-in-class drug candidates.

C4X Drug Discovery Engine

The Company has a unique software platform for determining the flexible 3D shapes of drug molecules from experimental in vitro data and this enables the rapid design and discovery of novel and potent drugs for diseases with high unmet medical need across broad therapeutic areas.

Targets are selected through traditional industry methods and C4X Discovery’s proprietary Taxonomy3® platform, which enables the discovery of targets that cause disease, rather than those that are simply associated with its symptoms. This provides the best starting point for drug discovery, biomarker identification and patient stratification, and significantly improves the chances of clinical success. The measurement, analysis and use of dynamic 3D-shapes is at the heart of C4XD's drug discovery engine. The focus and clarity that these data provide allows the Company to make rapid progress in developing new and better drugs at a fraction of the cost, compared to best industry practice.

 

The C4X Discovery management team has significant drug discovery and development expertise and experience, with a track record of value creation.

Clive Dix, PhD
Chief Executive Officer (Director)

  • Serially successful biotech entrepreneur
  • Exits include Convergence Pharmaceuticals (2015) and PowderMed Ltd (2006)
  • Ex UK Research Director, GlaxoWellcome
  • Former BIA Chairman


Craig Fox, PhD
Chief Scientific Officer (Director)

  • More than 20 years’ drug discovery experience from target selection to Phase 2 clinical studies
  • Previously Director of Respiratory Research at Pulmagen Therapeutics, Argenta
  • Managed several collaborations and partnerships at Pulmagen, including those with AstraZeneca, Chiesi, Domantis, Dr Reddy’s, SkyePharma and Teijin Pharma
  • Ex Bayer Pharmaceuticals


Brad Hoy
Chief Financial Officer (Director)

  •  
  • More than 20 years’ experience in the pharmaceutical and biotechnology industries
  • Previously Chief Financial Officer of Plethora Solutions Holdings plc, Chief Executive Officer of Xcellsyz Limited, and Senior Director of Geron Corporation’s stem-cell focused UK subsidiary
  • Co-founder of Seven Hills Venture Partners and previously served on the Board of Directors for e-Therapeutics plc for nine years.


Bhavna Hunjan
Head of Corporate Strategy and Development

  • 10 years’ experience across investment banking and strategic consultancy, providing commercial advice including business strategy, deal structuring and execution, product positioning, portfolio reviews, and regulatory change
  • Previously Senior Strategist at Cancer Research UK
  • Ex Lehman Brothers, Nomura International plc, and PricewaterhouseCoopers

 

THE BOARD

Eva-Lotta Allan
Non-Executive Chairman
Eva-Lotta has more than 30 years’ experience in the healthcare industry. During this time, she has been a Senior Executive and Board member at both public and private companies. Most recently, Eva-Lotta was Chief Business Officer (and previously a Board member) at Immunocore, where she held full responsibility for all aspects of business development and played an instrumental role in the $320 million fundraising in 2015. Prior to this, Eva-Lotta served as Chief Business Officer and member of the Executive Committee and Euronext IPO team for Ablynx NV. Eva-Lotta currently serves as Non-Executive Director and Member of the Corporate Governance Committee and the R&D Sub-Committee of Oslo listed company, Targovax ASA and is a Non-Executive Director of Crescendo Biologics. Until earlier this year, Eva-Lotta was also a Board Member of the UK BioIndustry Association (BIA).

 

Clive Dix, PhD
Chief Executive Officer (Director)
Clive has more than 30 years’ experience in life science research, with over 20 years in senior pharmaceutical industry positions and a degree and PhD in Pharmacology. His expertise includes an in-depth understanding of all facets of drug discovery and development, a broad knowledge of the science and commercial landscape of a variety of therapeutic areas and solid experience of the pharmaceutical business and finance community supporting the sector.

Clive was co-founder and chief executive of Convergence Pharmaceuticals Ltd, which was acquired by Biogen in January 2015.

Clive was previously co-founder and chief executive of PowderMed Ltd, a vaccines development company acquired by Pfizer in November 2006. Before that he was senior vice president, research and development and a Board member of PowderJect Pharmaceuticals plc until its acquisition by Chiron Vaccines in 2003. Clive began his career in industry at Ciba-Geigy and then GlaxoWellcome, where he left as UK research director in 2001. Clive is a recent past chairman of the BioIndustry Association, is currently non-executive chairman of Touchlight Genetics Ltd and Centauri Ltd, and is a non-executive member of the Medicines Discovery Catapult Board.

 

Craig Fox, PhD
Chief Scientific Officer (Director)
Craig is an experienced biologist having worked on and managed drug discovery and development projects for more than two decades, from initial target selection right through to investigating clinical efficacy and safety in Phase 2 patient studies. Craig joined C4X as Head of Biology in June 2015 before becoming Chief Scientific Officer in October later that year. Prior to joining C4XD, Craig was director of respiratory research at Pulmagen Therapeutics, a clinical stage company spun-out of Argenta in 2010. At Pulmagen, Craig managed several of its collaborations and partnerships, including those with AstraZeneca, Chiesi, Domantis, Dr Reddy’s, Skyepharma and Teijin Pharma. Craig was part of the Etiologics Team that merged with Argenta Discovery in 2004 and prior to this he worked for Bayer as a research scientist. Craig has a PhD in Respiratory Medicine from Birmingham University and a first-class biochemistry degree from the University of Surrey.

 

Brad Hoy
Chief Financial Officer (Director)
Brad has more than 20 years’ experience in the pharmaceutical and biotechnology industries and has held a number of senior financial and general management positions in both the UK and the US. Previously, Brad was chief financial officer of Plethora Solutions Holdings plc, an AIM-listed specialty pharmaceutical company, chief executive officer of Xcellsyz Limited, a UK venture capital-backed life science company, and senior director of Geron Corporation’s stem cell-focussed UK subsidiary. Brad is a co-founder of Seven Hills Venture Partners, a life sciences advisory firm, and previously served as non-executive director on the board of directors for e-Therapeutics plc for nine years.

 

Harry Finch, PhD
Non-Executive Director
Harry has significant experience within the pharmaceutical industry, specialising in medicinal chemistry, drug discovery and development. Currently he is an independent consultant working with a variety of small biotech companies and investors, many of which are in the oncology arena. Harry is also a non-executive director of Pulmocide Therapeutics and Artios Pharma Ltd. After attaining a PhD in Organic Chemistry, Harry worked at Ciba-Geigy AG (Now Novartis AG) and Roche Allen & Hanburys Limited, before joining GlaxoWellcome plc where he became director of Chemistry. Harry is an expert in the respiratory area of the pharma industry and is co-inventor of GSK’s successful asthma drug salmeterol (Serevent). In addition, he has worked across a range of therapeutic areas and at several biotechnology companies, including Ribotargets, Vernalis, Argenta and Pulmagen.

 

Alex Stevenson, PhD
Non-Executive Director
Alex has a proven track record in identifying, investing and growing businesses within the pharmaceutical sector. He is currently Chief Scientific Officer at 4D pharma plc.

From 2008, Alex was a director and shareholder of Aquarius Equity Partners Limited, and he joined the Board of C4XD as a Non-Executive Director following Aquarius’ investment in the Company. Prior to this, Alex worked for IP Group plc where he specialised in life science investments.

Alex has been involved in a number of private and public companies, including Nanoco Group plc, admitted to AIM in 2009; Retroscreen Virology Group plc, admitted to AIM in 2012; Tissue Regenix Group plc, admitted to AIM in 2010; and Auralis Limited, which, after investment through Aquarius Equity Partners Limited, delivered a seven-fold return through to its trade sale to ViroPharma Inc in 2010.

 

Natalie Walter
Non-Executive Director
Natalie is a corporate finance lawyer with more than 20 years of experience advising on international equity capital markets transactions in the healthcare sector. Most recently, Natalie was an Equity Partner at Covington & Burling LLP, advising boards on a range of strategic, transactional and general corporate finance matters, with particular expertise in advising on deals in the life sciences and med tech sectors. Natalie also sits as a Non-Executive Director on the Board of RSA (Holdings) Ltd, a boutique talent consultancy in life sciences.

 

 

Shareholder Information

Significant Shareholders

In so far as the company has been notified, the following table represents significant shareholders as at March 7th 2019;

Name Number of shares held Percentage of issued share capital
Aquarius Equity Partners (Manchester) 7,459,425 12.9%
Polar Capital (London) 5,555,555 9.6%
Canaccord Genuity Wealth Mgt (London) 5,216,924 9.0%
Calculus Capital (London) 4,609,889 8.0%
Baillie Gifford & Co (Edinburgh) 3,694,172 6.4%
Legal & General Investment Mgt (London) 3,552,000 6.1%
Mr Charles D Blundell (UK) 3,035,000 5.3%
Mr Andrew Almond (Regional (England)) 3,010,000 5.2%
Mr Andrew W Black (UK) 2,845,098 4.9%

AIM securities in issue: 57,792,636 (no shares held in Treasury)

The percentage of AIM securities not in public hands is 24.2%

Directors and their interests

Name Number of shares held Percentage of issued share capital
Clive James Dix 1,414,936 2.4%
Alexander James Stevenson 485,403 0.8%
Harry Finch 321,425 0.6%
Craig Fox 7,183 <0.1%

 

Address - Main Office

C4X Discovery Holdings PLC
Manchester One
53 Portland Street
Manchester
M1 3LD

United Kingdom

Email

[email protected]

Phone

+44 (0)161 235 5085

Address - London Office

Euston House
4th Floor
24 Eversholt Street
London
NW1 1AD

Nominated Advisor and Broker

Panmure Gordon (UK) Limited (NOMAD)

One New Change, London EC4M 9AF

Telephone: +44 (0)20 7886 2500

 
 
 
 
 
 

Auditors and Tax Advisors

KPMG LLP

1 The Embankment, Neville Street, Leeds LS1 4DW

Telephone: +44 (0)113 231 3000

 

 
 
 
 
 
 
 

Registrar

Capita Registrars Ltd

The Registry, 34 Beckenham Road, Beckenham, Kent BR3 4TU

Telephone: 0871 664 0300*, Overseas: +44 (0) 20 8639 3399

*Calls to 0871 numbers are charged at 10 pence per minute plus network extras. Lines are open from 8:30am to 5:30pm UK time, Monday to Friday.

 
 
 
 
 
 

Legal Advisors

Schofield Sweeney LLP

Springfield House, 76 Wellington Street, Leeds LS1 2AY

Telephone: +44 (0)1132 206270

 

 
 
 
 
 
 
 

Financial PR

Consilium

41 Lothbury, London, EC2R 7HG

Telephone: +44 (0)20 3709 5700

 

Address - Main Officemanchester one c4xd offices

C4X Discovery Holdings PLC
Manchester One
53 Portland Street
Manchester
M1 3LD

United Kingdom

Email

[email protected]

Phone

+44 (0)161 235 5085

Address - London Office

Euston House
4th Floor
24 Eversholt Street
London
NW1 1AD

 

 

View full C4XD profile View Profile
View All

Market Reports Including C4XD

VIEW ALL

Executive video interviews

VIEW ALL VIDEOS

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.